These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 27773665)

  • 21. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis.
    Payne H; Mkhize N; Otwombe K; Lewis J; Panchia R; Callard R; Morris L; Babiker A; Violari A; Cotton MF; Klein NJ; Gibb DM
    Lancet Infect Dis; 2015 Jul; 15(7):803-9. PubMed ID: 26043884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.
    Landman R; de Truchis P; Assoumou L; Lambert S; Bellet J; Amat K; Lefebvre B; Allavena C; Katlama C; Yazdanpanah Y; Molina JM; Petrov-Sanchez V; Gibowski S; Alvarez JC; Leibowitch J; Capeau J; Fellahi S; Duracinsky M; Morand-Joubert L; Costagliola D; Alvarez JC; Girard PM;
    Lancet HIV; 2022 Feb; 9(2):e79-e90. PubMed ID: 35120640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial.
    Puthanakit T; Saphonn V; Ananworanich J; Kosalaraksa P; Hansudewechakul R; Vibol U; Kerr SJ; Kanjanavanit S; Ngampiyaskul C; Wongsawat J; Luesomboon W; Ngo-Giang-Huong N; Chettra K; Cheunyam T; Suwarnlerk T; Ubolyam S; Shearer WT; Paul R; Mofenson LM; Fox L; Law MG; Cooper DA; Phanuphak P; Vun MC; Ruxrungtham K;
    Lancet Infect Dis; 2012 Dec; 12(12):933-41. PubMed ID: 23059199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection.
    Sharma S; Schlusser KE; de la Torre P; Tambussi G; Draenert R; Pinto AN; Metcalf JA; Neaton JD; Laeyendecker O;
    AIDS; 2019 Jul; 33(8):1335-1344. PubMed ID: 31157663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
    Pollard RB; Rockstroh JK; Pantaleo G; Asmuth DM; Peters B; Lazzarin A; Garcia F; Ellefsen K; Podzamczer D; van Lunzen J; Arastéh K; Schürmann D; Clotet B; Hardy WD; Mitsuyasu R; Moyle G; Plettenberg A; Fisher M; Fätkenheuer G; Fischl M; Taiwo B; Baksaas I; Jolliffe D; Persson S; Jelmert O; Hovden AO; Sommerfelt MA; Wendel-Hansen V; Sørensen B
    Lancet Infect Dis; 2014 Apr; 14(4):291-300. PubMed ID: 24525316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
    Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D;
    Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial.
    de Lastours V; LeGoff J; Brière J; Agbalika F; Boulet T; Lévy Y; Simon F; Aboulker JP; Molina JM
    HIV Med; 2014 Jan; 15(1):23-9. PubMed ID: 24007426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.
    Parkes-Ratanshi R; Wakeham K; Levin J; Namusoke D; Whitworth J; Coutinho A; Mugisha NK; Grosskurth H; Kamali A; Lalloo DG;
    Lancet Infect Dis; 2011 Dec; 11(12):933-41. PubMed ID: 21982529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial.
    Reynolds SJ; Makumbi F; Newell K; Kiwanuka N; Ssebbowa P; Mondo G; Boaz I; Wawer MJ; Gray RH; Serwadda D; Quinn TC
    Lancet Infect Dis; 2012 Jun; 12(6):441-8. PubMed ID: 22433279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial.
    Fairall L; Bachmann MO; Lombard C; Timmerman V; Uebel K; Zwarenstein M; Boulle A; Georgeu D; Colvin CJ; Lewin S; Faris G; Cornick R; Draper B; Tshabalala M; Kotze E; van Vuuren C; Steyn D; Chapman R; Bateman E
    Lancet; 2012 Sep; 380(9845):889-98. PubMed ID: 22901955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV.
    Pelchen-Matthews A; Mocroft A; Ryom L; Ross MJ; Sharma S; Coca S; Achhra A; Cornell E; Tracy R; Phillips A; Alonso MM; Toulomi G; Agan BK; Medland N; Wyatt CM;
    Kidney Int; 2024 Jul; 106(1):136-144. PubMed ID: 38697479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.
    Crowell TA; Colby DJ; Pinyakorn S; Sacdalan C; Pagliuzza A; Intasan J; Benjapornpong K; Tangnaree K; Chomchey N; Kroon E; de Souza MS; Tovanabutra S; Rolland M; Eller MA; Paquin-Proulx D; Bolton DL; Tokarev A; Thomas R; Takata H; Trautmann L; Krebs SJ; Modjarrad K; McDermott AB; Bailer RT; Doria-Rose N; Patel B; Gorelick RJ; Fullmer BA; Schuetz A; Grandin PV; O'Connell RJ; Ledgerwood JE; Graham BS; Tressler R; Mascola JR; Chomont N; Michael NL; Robb ML; Phanuphak N; Ananworanich J;
    Lancet HIV; 2019 May; 6(5):e297-e306. PubMed ID: 31000477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
    ; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
    Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From CD4-Based Initiation to Treating All HIV-Infected Adults Immediately: An Evidence-Based Meta-analysis.
    Song A; Liu X; Huang X; Meyers K; Oh DY; Hou J; Xia W; Su B; Wang N; Lu X; Xia H; Yang X; Chen H; Wu H
    Front Immunol; 2018; 9():212. PubMed ID: 29487595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial.
    Arenas-Pinto A; Grund B; Sharma S; Martinez E; Cummins N; Fox J; Klingman KL; Sedlacek D; Collins S; Flynn PM; Chasanov WM; Kedem E; Katlama C; Sierra-Madero J; Afonso C; Brouwers P; Cooper DA;
    Clin Infect Dis; 2018 Jul; 67(3):420-429. PubMed ID: 29538636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment eligibility and retention in clinical HIV care: A regression discontinuity study in South Africa.
    Bor J; Fox MP; Rosen S; Venkataramani A; Tanser F; Pillay D; Bärnighausen T
    PLoS Med; 2017 Nov; 14(11):e1002463. PubMed ID: 29182641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
    ; Lodwick RK; Sabin CA; Porter K; Ledergerber B; van Sighem A; Cozzi-Lepri A; Khaykin P; Mocroft A; Jacobson L; De Wit S; Obel N; Castagna A; Wasmuth JC; Gill J; Klein MB; Gange S; Riera M; Mussini C; Gutiérrez F; Touloumi G; Carrieri P; Guest JL; Brockmeyer NH; Phillips AN
    Lancet; 2010 Jul; 376(9738):340-5. PubMed ID: 20638118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Sharma S; Babiker AG; Emery S; Gordin FM; Lundgren JD; Neaton JN; Bakowska E; Schechter M; Wiselka MJ; Wolff MJ;
    HIV Med; 2015 Apr; 16 Suppl 1(0 1):30-6. PubMed ID: 25711321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.